NASD · Healthcare · Drug Manufacturers - Specialty & Generic · United Kingdom
Kiniksa Pharmaceuticals International Plc is a mid cap company (market value between $2 billion and $10 billion) in the Drug Manufacturers - Specialty & Generic industry.
Kiniksa Pharmaceuticals International is a biopharmaceutical company developing and commercializing therapies for cardiovascular diseases with unmet need. The company's primary approved product is ARCALYST, an interleukin-1 inhibitor used to treat recurrent pericarditis and other inflammatory conditions in the United States. The company is also advancing KPL-387, an investigational monoclonal antibody for recurrent pericarditis.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Kiniksa Pharmaceuticals International Plc stock.
Overvalued: intrinsic value $32.91 per share, market price $79.48, margin of safety -141.5% (as of 2026-10-19).
Discounting its cash flows at 9.0% (average of 3 methods) values the shares at $32.91; the price of $79.48 is 141% above that value, and 77% of that value comes from beyond year five.
Leak Score: 60/100 on 9 of 12 signals (Faint Leak).
17 more funds hold it; the full list is part of the paid plan.
All 84 Drug Manufacturers - Specialty & Generic stocks
24 more in this industry show a wider margin of safety.
KNSA is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 9.0% (average of 3 methods) values the shares at $32.91; the price of $79.48 is 141% above that value, and 77% of that value comes from beyond year five.
$32.91 per share (as of the 2026-10-19 close), against a market price of $79.48. That is a margin of safety of -141.5%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
60 out of 100, which we rate "Faint Leak", on 9 of 12 value investing signals.